Moderna says booster dose of its COVID-19 vaccine appears protective against Omicron


Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of T&Cs and Copyright Policy. Email to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at

Moderna’s Covid-19 booster shot elicits a strong antibody response against the Omicron variant of coronavirus, appearing to increase antibody levels even further than a third dose of the Pfizer vaccine.

The Boston-based biotech said its half-dose booster increased antibody levels 37-fold, compared with people who received just two doses, showing a similar level of immune response as when tackling the Delta variant. Two doses did induce a less robust result, down 2.9-fold against Omicron, compared with the wild type of the virus.

BioNTech and Pfizer have previously said their booster lifts antibody levels 25-fold, though the studies are not directly comparable. The pair are also preparing a shot targeted to Omicron, which it has said will be available by March.

But Stéphane Bancel, Moderna’s chief executive, on Monday said Moderna would also continue to invest in developing a vaccine targeted to the Omicron variant, in case it became necessary in the future, putting it into clinical trials early next year.

By Justgivemepositivenews Team